Sicherheitsaspekte der Therapie mit Biologika bei entzündlich rheumatologischen Erkrankungen

Zusammenfassung

Biologika haben zu einer rasanten Verbesserung der therapeutischen Optionen bei der medikamentösen Therapie rheumatologischer Erkrankungen geführt. Obgleich die Substanzen als sicher und gut verträglich gel-ten, ist eine abschließende Beurteilung des Sicherheitsprofils der einzelnen Substanzen noch nicht möglich. Dies liegt unter anderem daran, dass die zur Zulassung der Substanzen führenden kontrollierten Studien in der Regel nicht darauf ausgelegt sind, seltene Ereignisse zu erfassen und gerade für die neueren Substanzen noch kaum Daten aus der Analyse von Therapiekohorten vorliegen. In der vorliegenden Arbeit wurden die wichtigsten Sicherheitsaspekte unter besonderer Berücksichtigung substanzspezifischer Besonderheiten zusammengefasst

Summary

Biologics led to a rapid improvement of therapeutic options for rheumatologic diseases. Although they are generally considered to be safe and well tolerated, further longterm data (from registries) are awaited. However, judgment of side effects is difficult since controlled studies regularly were not designed to detect rare events like tumours or severe infections. Here, the most relevant safety aspects of the biologics currently available were summarized.

Schlüsselwörter

Biologika - rheumatoide Arthritis - Sicherheit - Infektionen

Keywords

Biologics - rheumatoid arthritis - safety - infections

• Literatur

• 1 Augustsson J, Eksborg S, Ernestam S. et al. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.. Ann Rheum Dis 2007; 66: 1462-1466.
• 2 Askling J, Fored CM, Brandt L. et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.. Ann Rheum Dis 2007; 66: 1339-1344.
• 3 Baecklund E, Ekbom A, Sparen P. et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.. BMJ 1998; 317: 180-181.
• 4 Furst DE, Keystone EC, Kirkham B. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases.. Ann Rheum Dis 2008; 67: iii2-iii25.
• 5 Danila MI, Patkar NM, Curtis JR. et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser?. Curr Opin Rheumatol 2008; 20: 327-333.
• 6 Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab.. Arthritis Rheum 2007; 56: 2715-2718.
• 7 Diel R, Hauer B, Loddenkemper R. et al. Recommendations for Tuberculosis Screening Before Initiation of TNF--Inhibitor Treatment in Rheumatic Diseases.. Pneumologie 2009; 63: 329-334.
• 8 Emery P, Sheeran T, Lehane PB. et al. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis.. Arthritis Rheum 2004; 50 (Suppl. 09) S659
• 9 Emery P, Szczepanski L, Szechinski J. et al. Sustained efficacy at 48 weeks after single treatment course of rituximab in patients with rheumatoid arthritis.. Arthritis Rheum 2003; 48: S439
• 10 Esteve M, Saro C, Gonzalez-Huix F. et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis.. Gut 2004; 53: 1363-1365.
• 11 Fleischmann RM, Tesser J, Schiff MH. et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.. Ann Rheum Dis 2006; 65: 1006-1012.
• 12 Furst DE, Breedveld FC, Kalden JR. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases.. Ann Rheum Dis 2007; 66 (Suppl. 03) III2-III22.
• 13 Geborek P, Bladstrom A, Turesson C. et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.. Ann Rheum Dis 2005; 64: 699-703.
• 14 Gelinck LBS, Teng YKO, Rimmelzwaan GF. et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with Rituximab.. Ann Rheum Dis 2007; 66: 1402-1403.
• 15 Gelinck LBS, van der Bijl AE, Visser LG. et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine.. Vaccine 2008; 26: 3528-3533.
• 16 Genovese MC, Cohen S, Moreland L. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.. Arthritis Rheum 2004; 50: 1412-1419.
• 17 Genovese MC, Breedveld FC, Emery P. et al Shaw Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients.. Ann Rheum Dis 2009. Jan 20, published online
• 18 Govindappa V, Hicks S, Wichter M, Jolly M. Progressive multifocal leukoencephalopathy in systemic lupus erythematosus.. Arthritis Rheum 2007; 57: 352-354.
• 19 Haroon N, Inman RD. Infectious complications of biological therapy.. Current Opinion in Rheumatology 2009; 21: 397-403.
• 20 Harris HE. Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus treated with Rituximab.. Rheumatology 2008; 47: 225-226.
• 21 Holle JU, Schinke S, Gross WL. Infektionsrisiko durch Biologika.. Z Rheumatol 2008; 67: 295-304.
• 22 Ince A, Rusche W, Daud U. et al. Etanercept in the treatment of rheumatoid arthritis patients with chronic hepatitis C infection.. AnnRheum Dis 2002; 61 (Suppl. 01) 191
• 23 Jones G, Sebba A, Gu J. et al Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study.. Ann Rheum Dis 2009. [Epub ahead of print]
• 24 Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis.. Bull Rheum Dis 1999; 48: 1-4.
• 25 Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.. Rheum Dis Clin North Am 1998; 24: 593-614.
• 26 Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.. Current Opinion in Rheumatology 2008; 20: 443-449.
• 27 Keane J, Gershon S, Wise RP. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent.. N Engl J Med 2001; 345: 1098-1104.
• 28 Keystone EC. Safety of biologic therapies – an update.. J Rheumatol Suppl 2005; 74: 8-12.
• 29 Keystone E, Fleischmann R, Emery P. et al. Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis. An Open-Label Extension Analysis.. Arthritis Rheum 2007; 56: 3896-3908.
• 30 Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?. Arthritis Rheum 2004; 50: 1040-1050.
• 31 Khraishi M. Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis. J.. Rheumatology 2009; 36 (Suppl. 82) 25-32.
• 32 Kneitz C, Wiendl H. Progressive multifokale Leukoenzephalopathie bei rheumatologischen Erkrankungen. Z.. Rheumatol 2008; 67: 292-294.
• 33 Lequerre T, Vittecoq O, Klemmer N. et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology.. J Rheumatol 2006; 33: 1307-1314.
• 34 Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease.. Arthritis Rheum 2008; 58: 5-14.
• 35 Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis.. Drugs 2000; 59: 1341-1359.
• 36 Mielke F, Schneider-Obermeyer J, Dorner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma.. Ann Rheum Dis 2008; 67: 1056-1057.
• 37 Nishimoto N, Miyasaka N, Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.. Mod Rheumatol 2009; 19: 12-19.
• 38 Ostensen M, Lockshin M, Doria A. et al. Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs.. Rheumatology 2008; 47 (Suppl. 03) iii28-31.
• 39 Prior P, Symmons DP, Hawkins CF. et al. Cancer morbidity inrheumatoid arthritis.. Ann Rheum Dis 1984; 43: 128-131.
• 40 Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments of rheumatoid arthritis: meta-analysis of randomised placebo-controlled trials.. Ann Rheum Dis 2009; 68: 25-32.
• 41 Salliot C, Gossec L, Ruyssen-Witrand A. et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.. Rheumatology 2007; 46: 327-334.
• 42 Setoguchi S, Schneeweiss S, Avorn J. et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.. Am Heart J 2008; 156: 336-341.
• 43 Sibilia J, Westhovens R. Safety of T-cell costimulation modulation with abatacept in patients with rheumatoid arthritis.. Clin Exp Rheumatol 2007; 25 (5 Suppl 46) S46-56.
• 44 Simon TA, Smitten AL, Franklin J. et al Malignancies in the rheumatoid arthritis abatacept clinical development program: An epidemiological assessment.. Ann Rheum Dis 2008; Dec 3 [Epub ahead of print]
• 45 Simsek I, Erdem H, Pay S. et al. Optic neuritis occurring after antitumour necrosis factor a therapy.. Ann Rheum Dis 2007; 66: 1255-1258.
• 46 Slifman NR, Gershon SK, Lee JH. et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.. Arthritis Rheum 2003; 48: 319-324.
• 47 Smitten A, Covucci A, Simon T. Descriptive analysis of serious infections, hospitalized infections and malignancies over time in the abatacept clinical development program: a safety update with 10,000 person-years of exposure.. Ann Rheum Dis 2008; 67 (Suppl II) 338
• 48 Smolen JS, Beaulieu AD, Dikranian A. et al Safety of Tocilizumab in Patients with Rheumatoid Arthritis: Pooled Analysis of Five Phase 3 Clinical Trials Presentation: 1669, ACR 2008
• 49 Smolen S, Keystone EC, Emery P. et al Working Group on the Rituximab Consensus Statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-150.
• 50 Solomon DH, Tyndall A, Gabriel SE, Dougados M. Rheumatology gone global.. Arthritis Rheum 2008; 59: 1369-1370.
• 51 Stone JH, Holbrook JT, Marriott MA. et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept Trial.. Arthritis Rheum 2006; 54: 1608-1618.
• 52 Strangfeld A, Listing J, Herzer P. et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.. JAMA 2009; 301: 737-744.
• 53 US Food and Drug Administration. FDA alert: rituximab (marketed as Rituxan) December. 2006 http://www.fda.gov/cder/drug/InfoSheets/HCP/ri tuximab.pdf
• 54 Vassilopoulos D, Calabrese LH. Risks of immuno-suppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.. Curr Opin Rheumatol 2007; 19: 619-625.
• 55 Weinblatt M, Schiff M, Goldman A. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.. Ann Rheum Dis 2007; 66: 228-234.
• 56 Weinblatt M, Combe B, Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study.. Arthritis Rheum 2006; 54: 2807-2816.